Tumour growth was stunted by trametinib in N-Ras mutant (Q61K) neuroblastoma and EML4-ALK fusion-positive NSCLC xenografts, but not in the ALK-addicted neuroblastoma tumours [114]. This evidence concerns the gene ALK and non-small cell lung carcinoma.